OA11636A - Therapeutic formulation for administering tolterodine with controlled release. - Google Patents

Therapeutic formulation for administering tolterodine with controlled release. Download PDF

Info

Publication number
OA11636A
OA11636A OA1200000309A OA1200000309A OA11636A OA 11636 A OA11636 A OA 11636A OA 1200000309 A OA1200000309 A OA 1200000309A OA 1200000309 A OA1200000309 A OA 1200000309A OA 11636 A OA11636 A OA 11636A
Authority
OA
OAPI
Prior art keywords
tolterodine
sérum
formulation
métabolite
daims
Prior art date
Application number
OA1200000309A
Other languages
English (en)
Inventor
Torkel Gren
Bengt Hallen
Ulla Hoeck
Bo Kreilgard
Helle Kristensen
Lisbeth Nilvebrant
Birgitta Olsson
Lene Orup Jacobsen
Anders Ringberg
Jan Strombom
Martin Wikberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11636(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of OA11636A publication Critical patent/OA11636A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
OA1200000309A 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release. OA11636A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (1)

Publication Number Publication Date
OA11636A true OA11636A (en) 2004-09-03

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000309A OA11636A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.

Country Status (31)

Country Link
US (1) US6770295B1 (fr)
EP (2) EP1039882B1 (fr)
CN (1) CN1239152C (fr)
AP (1) AP1529A (fr)
AR (1) AR029311A1 (fr)
AT (1) ATE487471T1 (fr)
AU (1) AU745190B2 (fr)
BG (1) BG65168B1 (fr)
CA (1) CA2311755C (fr)
CY (1) CY1111088T1 (fr)
CZ (1) CZ302630B6 (fr)
DE (1) DE69942928D1 (fr)
DK (1) DK1039882T3 (fr)
EA (1) EA002720B1 (fr)
GE (1) GEP20043354B (fr)
HK (1) HK1034664A1 (fr)
HU (1) HUP0100437A3 (fr)
ID (1) ID25824A (fr)
IL (1) IL136294A (fr)
IS (1) IS2976B (fr)
ME (1) ME00850B (fr)
MY (1) MY127946A (fr)
NO (1) NO329830B1 (fr)
NZ (1) NZ504618A (fr)
OA (1) OA11636A (fr)
PT (1) PT1039882E (fr)
SI (1) SI1039882T1 (fr)
SK (1) SK287111B6 (fr)
TR (1) TR200001998T1 (fr)
UA (1) UA72882C2 (fr)
WO (1) WO2000012069A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (fr) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
EE05191B1 (et) * 1999-11-11 2009-08-17 Pharmacia Ab Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
MXPA04003866A (es) * 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
WO2004054560A1 (fr) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
KR20050096147A (ko) * 2003-01-22 2005-10-05 피저 헬스 에이비 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Compositions pharmaceutiques de tolterodine a liberation controlee et leurs procedes de preparation
ATE493981T1 (de) 2003-11-04 2011-01-15 Supernus Pharmaceuticals Inc Einmal tägliche dosierformen von trospium
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005105036A1 (fr) * 2004-04-28 2005-11-10 Natco Pharma Limited Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration
EP1629834A1 (fr) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (fr) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methode et compositions de traitement des affections du snc
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
WO2007122015A1 (fr) * 2006-04-21 2007-11-01 Synthon B.V. Perles de tolterodine
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
EP2762132A1 (fr) 2007-04-25 2014-08-06 Cytochroma Inc. Compositions orales à libération contrôlée comprenant des composés de vitamine D et un véhicule cireux
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (fr) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (fr) 2010-02-04 2011-08-11 Synthon Bv Microgranule de toltérodine
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20130195957A1 (en) * 2010-08-03 2013-08-01 Hisamitsu Pharmaceutical Co., Inc. Patch and method for enhancing adhesion force of the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
TWI747893B (zh) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素ｄ治療之方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
JP3786684B2 (ja) 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (fr) 1994-10-21 1996-05-02 Leiras Oy Systeme d'administration orale a liberation lente contenant de l'oxybutynine
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
EP0927034A1 (fr) * 1996-09-19 1999-07-07 American Home Products Corporation Procede de traitement de l'incontinence urinaire

Also Published As

Publication number Publication date
HUP0100437A2 (hu) 2002-05-29
GEP20043354B (en) 2004-04-13
NO329830B1 (no) 2011-01-03
CY1111088T1 (el) 2015-06-11
SI1039882T1 (sl) 2011-01-31
CN1239152C (zh) 2006-02-01
ME00850B (fr) 2008-08-07
IS5537A (is) 2000-06-15
AU5891899A (en) 2000-03-21
HUP0100437A3 (en) 2002-08-28
EA200000468A1 (ru) 2000-12-25
CZ302630B6 (cs) 2011-08-10
AR029311A1 (es) 2003-06-25
SK287111B6 (sk) 2009-12-07
AP2000001823A0 (en) 2000-06-30
MY127946A (en) 2007-01-31
IL136294A0 (en) 2001-05-20
AP1529A (en) 2006-01-03
UA72882C2 (uk) 2005-05-16
ID25824A (id) 2000-11-09
WO2000012069A1 (fr) 2000-03-09
EP2153825A1 (fr) 2010-02-17
IS2976B (is) 2017-07-15
EP1039882B1 (fr) 2010-11-10
EA002720B1 (ru) 2002-08-29
AU745190B2 (en) 2002-03-14
BG104476A (en) 2000-12-29
BG65168B1 (bg) 2007-05-31
SK7492000A3 (en) 2001-02-12
DK1039882T3 (da) 2011-01-24
NO20002977L (no) 2000-06-09
CZ20001924A3 (cs) 2001-04-11
HK1034664A1 (en) 2001-11-02
CA2311755C (fr) 2010-03-23
NZ504618A (en) 2002-09-27
CA2311755A1 (fr) 2000-03-09
US6770295B1 (en) 2004-08-03
DE69942928D1 (de) 2010-12-23
CN1287484A (zh) 2001-03-14
TR200001998T1 (tr) 2001-01-22
IL136294A (en) 2004-02-08
EP1039882A1 (fr) 2000-10-04
ATE487471T1 (de) 2010-11-15
PT1039882E (pt) 2011-01-03
NO20002977D0 (no) 2000-06-09

Similar Documents

Publication Publication Date Title
OA11636A (en) Therapeutic formulation for administering tolterodine with controlled release.
ES2353765T3 (es) Formulación terapeútica para administrar tolterodina con liberación controlada.
US6630162B1 (en) Pharmaceutical formulation and its use
TWI222879B (en) Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder
US9375410B2 (en) Modified release dosage forms of skeletal muscle relaxants
MXPA00005215A (en) Therapeutic formulation for administering tolterodine with controlled release